E22.0
Acromegaly and pituitary gigantism
Clinical Classification Guidelines
Inclusion Terms
- Overproduction of growth hormone
Excludes Type 1
- constitutional gigantism (E34.4)
- constitutional tall stature (E34.4)
- increased secretion from endocrine pancreas of growth hormone-releasing hormone (E16.8)
Medical Intelligence & Overview
Acromegaly and pituitary gigantism are rare conditions caused by an overproduction of growth hormone, typically due to a benign tumor in the pituitary gland. While both involve excess growth hormone, they differ mainly in the age of onset and the areas of the body affected. Acromegaly develops in adults, leading to thickening of bones and soft tissues, whereas pituitary gigantism begins in childhood or adolescence, resulting in excessive growth in height and overall size. These conditions can significantly impact physical appearance and health, making early diagnosis and management important.
Causes & Symptoms
Clinical Causes: Benign tumor (adenoma) of the pituitary gland producing excess growth hormone Rarely, genetic syndromes that predispose to hormone-secreting tumors Less commonly, growth hormone-secreting tumors elsewhere in the body
Key Symptoms: Enlarged hands and feet Facial feature changes, such as a protruding jaw and enlarged nose Joint pain or stiffness Swollen soft tissues, leading to a broadening of the hands and feet Deepening of the voice Increased sweating and oily skin Headaches and vision problems due to tumor pressure In cases of pituitary gigantism, excessive height and overall growth Possible interference with hormone balance, leading to changes in menstrual cycles, erectile dysfunction, or other endocrine issues
Diagnostic & Treatment
Diagnosis Path: Measuring fasting growth hormone levels and insulin-like growth factor-1 (IGF-1), which reflect long-term growth hormone activity Oral glucose tolerance test to assess growth hormone suppression Magnetic resonance imaging (MRI) of the pituitary gland to identify tumors Visual field testing if there are symptoms of nerve compression Additional blood tests to evaluate related hormone levels
Treatment Protocols: Surgical removal of the pituitary tumor through transsphenoidal surgery Medications such as somatostatin analogs (e.g., octreotide), growth hormone receptor antagonists (e.g., pegvisomant), or dopamine agonists to control hormone secretion Radiation therapy to shrink or control tumor growth when surgery or medication is insufficient Management of associated complications, including metabolic disorders, cardiovascular health, and joint issues Regular monitoring of hormone levels and imaging studies to assess treatment effectiveness
Clinical Advice & FAQs
Billing Guidance
Is E22.0 a billable ICD-10 code?
Yes, E22.0 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report E22.0?
Clinical documentation must specify the nature of Acromegaly and pituitary gigantism and any associated comorbidities for accurate reporting.
Cite this Clinical Reference